Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
J Pediatr Hematol Oncol
.
2001 Mar-Apr;23(3):150-2.
doi: 10.1097/00043426-200103000-00005.
Authors
C P Reynolds
1
,
R C Seeger
Affiliation
1
Division of Hematology-Oncology, Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, USA.
PMID:
11305717
DOI:
10.1097/00043426-200103000-00005
No abstract available
MeSH terms
Bone Marrow Neoplasms / diagnosis*
Humans
Neoplasm, Residual
Neuroblastoma / diagnosis*
Neuroblastoma / therapy
Prognosis